drugset
drugset / Trial / NCT07181538

Phase 1 Study of JLP-2302 and JP-1366: PK and Safety in Healthy Volunteers

NCT07181538 ↗

Phase 1 Completed 55 enrolled Onconic Therapeutics Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

This study aims to evaluate the pharmacokinetics and the safety after administration of "JLP-2302" and "JP-1366" in healthy volunteers.

Timeline

Start
2025-02-04
Primary completion
2025-02-20
Completion
2025-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject JLP-2302 Unknown — —
Subject JP-1366 Unknown — —

Indications

No indication recorded.